638P Unmet needs and preference of Chinese HR+HER2- eBC patients across the treatment journey: Results from patient survey
C. Sun, S. Wang, Y. Nie, X. Mo et autres
Adjuvant intensive therapy with CDK4/6 inhibitors significantly improves outcomes in patients with HR+HER2- early-stage breast cancer and indicates that a broad population of Stage II-III is at high risk of recurrence. Comprehensive understanding of patients' awareness of recurrence risk and treatment expectations …
cn (code pays fourni par la source)
0 citations
ESMO Open